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Abstract. Although there has been an increasing incidence of bacteremia caused by extended-spectrum beta-
lactamase (ESBL)–producing Enterobacteriaceae (ESBL-E) across South East Asia, there are sparse data from the Lao
PDR, where laboratory capacity for antimicrobial resistance surveillance is limited. We, therefore, retrospectively
reviewed bacteremia caused by ESBL-producing Escherichia coli andKlebsiella pneumoniae between 2010 and 2014 at
Mahosot Hospital, Vientiane, Lao PDR. Clinical and laboratory data relating to all episodes of ESBL-E bacteremia were
reviewed over the 5-year period and compared with non–ESBL-E bacteremia. Blood cultures positive for E. coli or
K. pneumoniae were identified retrospectively from laboratory records. Clinical and laboratory data were extracted from
research databases and case notes and analyzed using STATA. Between 2010 and 2014, we identified 360 patients with
E. coli (n = 249) or K. pneumoniae (n = 111) bacteremia, representing 34.8% of all patients with clinically significant
bacteremia. Seventy-two (20%) isolates produced ESBL; E. coli accounted for 15.3% (55/360) and K. pneumoniae for
4.7% (17/360), respectively. The incidenceof ESBL-producingE. colibacteremia roseduring the studyperiod.Bymultiple
logistic analysis, reported antibiotic use in the previousweekwas significantly associatedwith ESBL positivity (P < 0.001,
odds ratio 3.89). Although multiresistant, most ESBL-producing E. coli and K. pneumoniae remained susceptible to
meropenem (65/65; 100%) and amikacin (64/65; 98.5%). We demonstrated an alarming increase in the incidence of
ESBL-Easacauseof bacteremia inVientianeduring the studyperiod. This has implications for empiric therapyof sepsis in
Laos, and ongoing surveillance is essential.
INTRODUCTION
Bloodstream infection is a major cause of morbidity and
mortality, comparable with major traumatic injury, myocar-
dial infarction, and stroke with an annual incidence of
140–160 per 100,000 population.1,2 Antimicrobial resistance
(AMR) leads to increased mortality, length of hospital stay,
and hospital costs associated with bloodstream infections,
including both community-onset and hospital-acquired
bacteremia.3,4 Gram-negative bacteria belonging to the
family Enterobacteriaceae are associated with infections
ranging fromminor urinary tract infections to life-threatening
bacteremia. Enterobacteriaceae, especially Escherichia coli
and Klebsiella pneumoniae, are becoming a major threat to
public health because of their ability to acquire resistance to
most current antibiotics, especially third-generation cepha-
losporins, such as ceftriaxone, through the production of
extended-spectrum beta-lactamases (ESBLs).5 The WHO has
listed ESBL-producing Enterobacteriaceae (ESBL-E) as critical
priority pathogens for research and development of new
antibiotics.6 Extended-spectrum beta-lactamase–producing
Enterobacteriaceae have emerged as important pathogens in
many countries in the Asia–Pacific region, such as India and
China where ESBL-producing isolates account for 77% and
48% of Enterobacteriaceae from intra-abdominal infections,
respectively.7 LaoPDR is a land-locked country, surroundedby
countries with high incidence rates of ESBL-E infection,8,9 al-
though it has few microbiology laboratories and data on AMR
are, therefore, scarce. Phetsouvanh et al.10 demonstrated that
Gram-negative bacteria accounted for 77% of community-
acquired bacteremia in Lao PDR between 2000 and 2004, with
E. coli and K. pneumoniae accounting for 12% and 4%, re-
spectively. The first ESBL-producing E. coli was identified in
Mahosot Hospital, Vientiane, in 2004, and between 2004 and
2009, 9%ofE.coli isolated frombloodwereESBLproducers.11
A study of preschool children in and around Vientiane in 2011
found that 23%were colonizedwith ESBL-E,mainlyE. coli and
K. pneumoniae, and colonization was strongly associated with
prior antibiotic use.12 Cephalosporins, particularly ceftriaxone,
are widely used for empirical treatment of febrile patients in
Laos, but the lack of access to diagnostic microbiology and
AMRsurveillance datamean that clinicians are largely unaware
of the extent of the AMR problem, leading to delays in initiating
appropriate treatment. Therefore, we retrospectively reviewed
the proportion, clinical features, risk factors, and antibiotic
susceptibility profiles of E. coli and K. pneumoniae causing
bacteremia at Mahosot Hospital, Vientiane, Laos, between
2010 and 2014.
MATERIALS AND METHODS
Mahosot Hospital in Vientiane, Laos, is a central, tertiary
hospital with 450 beds, which serves a population of ap-
proximately 800,000 people in the immediate catchment, but
also acts as a referral center for other peripheral and provincial
hospitals. It receives approximately 19,000 admissions per
year (Mahosot Summary Report 2010–2014, unpublished
data). The Mahosot Hospital Microbiology Laboratory pro-
vides a bacterial culture service for Mahosot Hospital and
several other hospitals in Laos, supported by the Lao-Oxford-
Mahosot Hospital-Wellcome Trust Research Unit. It receives
approximately 6,500 blood culture sets annually, of which
4,600 come from inpatients atMahosot Hospital. As part of an
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ongoing study of the causes of fever at Mahosot Hospital
since 2000 (the “UI-study”), a set of blood cultures (two aer-
obic bottles [Pharmaceutical Factory Number 2, Vientiane,
Laos]) is sent by the responsible clinician from all patients
admitted with suspected community-acquired bacteremia,
subject to written informed consent. Clinical and laboratory
information at the time of study admission is recorded on
standard forms and databases. Blood cultures were pro-
cessed manually as described,10 with significant isolates
identified phenotypically (by API 20E [bioMe´rieux, Basing-
stoke, United Kingdom] in the case of Enterobacteriaceae).
Significant isolates were tested for antimicrobial susceptibility
by disk diffusion according to the current methods of the
Clinical and Laboratory Standards Institute. Any E. coli or
Klebsiella spp. resistant to cefpodoxime, ceftriaxone or
cefotaxime, or ceftazidime was tested for ESBL activity by
disk diffusion against ceftazidime and cefotaxime with and
without clavulanic acid: an increase in zone diameter ³ 5 mm
for either agent in the presence of clavulanic acid was con-
sidered as positive for ESBL.13 Molecular detection methods
were not used in this study.
Data collection and analysis. We retrospectively reviewed
laboratory records to identify all Mahosot Hospital patients who
had blood cultures positive for E. coli and K. pneumoniae be-
tween 2010 and 2014. Clinical and microbiological data (in-
cluding reported antibiotic use in the previous week) were
exported from the UI-study database into Microsoft Excel
(Microsoft Corporation, Redmond, WA). Missing and in-
consistent data were checked from patient charts (where avail-
able) and primary laboratory sources (e.g., laboratory work
books). Where the results could not be reconciled, the organisms
were re-cultured from the stock frozen at −80C and retested.
Data analysis was performed using STATA v 14.2 (Stata Cor-
poration, College Station, TX). Data were summarized using
descriptive statistics such as number, percentage, median,
mean, and 95% CI. Categorical variables were compared using
the chi-square test or Fisher’s exact test. We included the sta-
tistically significant (P < 0.05) and relevant variables from the
univariableanalysis inamultiple logistic regressionmodelusinga
backward stepwise approach to identify factors associated with
ESBL positivity and mortality associated with ESBL positivity.
RESULTS
During the period 2010–2014, the laboratory received 18,319
blood culture sets from 15,665 patients, of whom 6.6% (1,032/
15,665) grew clinically significant organisms (i.e., excluding du-
plicates). Escherichia coli and K. pneumoniae together accoun-
ted for 34.8% (360/1,032) of all clinically significant isolates, of
which 90% were classed as community-acquired bacteremia,
that is, taken within 48 hours of hospital admission. Of these, 72
(20%) were ESBL positive and 288 (80%) were ESBL negative.
In the ESBL-producing group, E. coli and K. pneumoniae
accounted for 15.3% (55/360) and 4.7% (17/360), respectively.
The proportion of ESBL-producing E. coli was greater than
ESBL-producingK.pneumoniae (15.3%versus4.7%,P<0.001)
throughout the study period. The proportion ofE. coli-producing
ESBL increasedmore than 4-fold from four (7.8%) cases in 2010
to 17 (34.7%) cases in 2014 (Figure 1).
Basic clinical and epidemiological features of the patients
are shown in Table 1.Of the 360patients, 143 (40%)weremale
and the overall median interquartile range (IQR) age was 57
(42–70) years. Patients with ESBL-positive infections were
significantly younger than those with ESBL-negative infec-
tions (P = 0.03). Most of the patients presented with acute
illness (median [IQR] days of illness∼ 3 [2–7]) and therewas no
difference between the ESBL-positive and ESBL-negative
groups in terms of clinical presentation.
Details of risk factors and outcomes are shown in Table 1.
By univariable analysis, the presence of renal calculi (odds
ratio [OR] 3.38, 95% CI: 1.20–9.48), chronic renal failure (OR
3.06, 95% CI: 1.14–8.24) and reported antibiotic use in the
previousweek (OR4.40, 95%CI: 2.21–8.79) were significantly
associated with ESBL positivity (P < 0.05 for all). However, by
multiple logistic regression, only reported antibiotic use in the
previous week was independently significantly associated
with ESBL positivity (P < 0.001, OR 3.89, 95% CI: 1.85–8.18).
Unfortunately, only 203 (56%) of 360 patients had outcome
data available; 144/203 (71%) were discharged alive, but the
proportion of patients who died or were discharged moribund
(a common outcome in Laos for cultural reasons) was signif-
icantly higher in the ESBL-positive group than in the ESBL-
negative patients. However, patient outcomes were not
independently associated with ESBL positivity by multiple
logistic regression (P = 0.21). In the univariate analysis, patients
infected with ESBL-producing K. pneumoniae were signifi-
cantly younger and less frequently reported a history of fever
compared with those infected with ESBL-producing E. coli.
There were no other significant differences between two path-
ogens in term of clinical presentations, co-morbidities, and
outcomes (Table 2).
All ESBL-producing E. coli and K. pneumoniae in this study
were susceptible to imipenem and/or meropenem (Table 3).
The proportion susceptible to gentamicin declined sharply in
2011 but was relatively stable from 2012 to 2014, whereas all
isolates were sensitive to amikacin apart from a single isolate
in 2014 from a patient with biliary sepsis. For other groups of
antibiotics, susceptibility rates were relatively consistent, with
no obvious trend during the study period: chloramphenicol
was active against 47–68% of isolates, followed by ofloxacin
andciprofloxacin (33–57%susceptible). Fewer than half of the
isolates appeared susceptible in vitro to co-amoxiclav and
fewer than 30% to ceftazidime and co-trimoxazole.
DISCUSSION
Since2000, bloodstream isolatesofE. coliandK.pneumoniae
have been routinely screened for ESBL production at Mahosot
Hospital. Results are reported to clinicians in real time. Since the
first ESBL-producing E. coli identified in 2004, there has been a
steady increase in theproportionofbacteremiacausedbyESBL-
E in Vientiane. We previously reported that 9% of E. coli causing
bloodstream infection between 2004 and 2009 were ESBL pro-
ducers.11 This retrospective study confirms that the overall pro-
portion of Enterobacteriaceae causing bacteremia that produce
ESBL further increased 3-fold from 2010 to 2014.
All ESBL-E should not be considered as a homogeneous
group.14 The reasons for the differences are unclear, but imply
distinct epidemiological differences between the two species.
Extended-spectrum beta-lactamase-producing E. coli was sig-
nificantlymore common than ESBL-producingK. pneumoniae as
a cause of bacteremia in our population (15.28% versus 4.72%,
P < 0.001). Interestingly, our study demonstrated different chro-
nological trends for ESBL-producing E. coli bacteremia, which
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increased in proportion nearly 5-fold during the study period, and
ESBL-producing K. pneumoniae bacteremia, which initially dou-
bled (from 12.5% in 2010 to 26.1% in 2012) but then declined to
4%and9.5%in2013and2014, respectively.Similarobservations
havebeenmade inotherstudies.15Wealsoobserved thatpatients
with ESBL-producing K. pneumoniae bacteremia were younger
than those with ESBL-producing E. coli bacteremia, which has
also been described by others.16
Overall, this increase in the frequency of bacteremia caused
by ESBL-E has significant implications for the empirical man-
agement of community-acquired sepsis, which is usually treat-
ed with ceftriaxone in Laos. Moreover, most of these isolates
were multiresistant, leading to severe problems in selecting
appropriate agents to replace ceftriaxone. However, the picture
is not entirely bleak, as the proportion of ESBL-E as causes of
bacteremia is still lower in Laos than in some neighboring
countries,whichhavebeenhigh formanyyears.7Theproportion
of E. coli and K. pneumoniae causing community-acquired
bacteremia that are ESBL positive varies between countries
across South East Asia, ranging from 11.8% to 50% for E. coli
and 11.4% to 43.8% for K. pneumoniae, respectively.17–20 For
example, between 2004 and 2010, a retrospective, multicenter
surveillance study in all provincial hospitals in northeast Thai-
land, which lies to the south and west of Laos across the
Mekong river, found thatESBLwasproducedby11.8%ofE.coli
and 11.4% of K. pneumoniae causing bacteremia, with an in-
creasing year-on-year trend.17 In Cambodia between July 2007
and December 2010, 47.7% of E. coli and 43.8% of
K. pneumoniae causing bacteremia produced ESBL.18 A retro-
spective study conducted at the National Hospital for Tropical
Diseases in Hanoi, Vietnam, between January 2011 and De-
cember 2013 demonstrated that the proportions of E. coli and
K. pneumoniae causing bacteremia that produced ESBL were
45%and12.3%, respectively.19Amore recent studyconducted
at three hospitals in Yangon, Myanmar, from July to December
2014, found that 50% of E. coli and 43% of K. pneumoniae
causing bacteremia produced ESBL.20 In a prospective multi-
center study conducted in 28 tertiary hospitals across China
from September 2013 to November 2014, the corresponding
proportions were 55.5% and 16.7%, respectively.21 The fact
that Laos is still lagging behind these countriesmeans that there
may be a chance to intervene before the problem reaches the
size of that in its neighbors. This should inform rapid policy de-
cisions and implementation to prevent the situation worsening.
FIGURE 1. Extended-spectrum beta-lactamase (ESBL) production in Escherichia coli and Klebsiella pneumoniae blood culture isolates between
2010 and 2014 at Mahosot Hospital, Vientiane, Lao PDR.
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Our retrospective study found a number of factors that were
associated with ESBL production in patients with E. coli and
K. pneumoniaebacteremia, including renal calculi, chronic renal
failure, and reported antibiotic use in the previous week. How-
ever, only reported antibiotic use in the previousweek remained
as a significant risk factor by multiple logistic regression. The
recordedantibioticusedatadidnot, however, include thedetails
ofantibioticclass, lengthof,or reasons forprescription.Previous
studies have also shown that healthcare-associated infection,
obstructive urinary tract disease, chronic kidney disease, cere-
brovascular disease, heart failure, previous major surgery, ma-
lignancies, and previous use of antibiotics were associatedwith
bloodstream infection caused by ESBL-producing E. coli and
K. pneumoniae.21–26 Furthermore, prior use of several different
classes of antimicrobials, including extended-spectrum ceph-
alosporins, fluoroquinolones, aminoglycosides, co-trimoxazole,
and carbapenems, has repeatedly been associated with ESBL-
producing E. coli and K. pneumoniae bacteremia,23,24,27–32 and
a study from Spain showed that receipt of more than two dif-
ferent antibiotic classes in the preceding 90 days was the only
predictor of ESBL production in patients with E. coli or
K. pneumoniae bacteremia (OR 2.29, 95% CI: 1.35–3.88).33
Whether the link observed in our studywascausal orwas simply
a reflection of the fact that blood cultures are more likely to be
positive in patients on antibiotics who are infected with multi-
resistant organisms than with susceptible organisms is impos-
sible to say. However, inappropriate antibiotic prescribing is
common in Laos and there is a clear need to educate local
clinicians about diagnostic stewardship and the prudent use of
antibiotics.34
Several studies have demonstrated that the mortality rate
associated with ESBL-producing E. coli and K. pneumoniae
bacteremia is significantly (30–50%) higher than that of non–
ESBL-producing organisms,35–38 as it was in our study and
associatedwith longer hospital stays and costs.39 The selection
of appropriate antimicrobial therapy is an essential intervention
to improve patient outcomes.40 This is particularly important
during empirical treatment, although susceptibility results are
still pending or in patients who are critically ill and are not
responding to initial treatment with agents such as third-
generation cephalosporins. This study has shown that local
ESBL-producingE. coli andK. pneumoniae causing bacteremia
in Vientiane have a high rate of co-resistance to other groups of
antibiotics but remain susceptible to meropenem andmostly to
amikacin. This is consistent with previous studies from other
centers.41–43 The suggested empirical treatment for patients
with suspected sepsis in Mahosot Hospital is currently cef-
triaxone,44 but this study raises the question as to whether this
TABLE 1
Characteristics and symptoms of patients with ESBL-negative and ESBL-positive Escherichia coli and Klebsiella pneumoniae bacteremia at the
time of study admission (data shown as number (%) unless indicated)
Total (n = 360) ESBL negative (n = 288) ESBL positive (n = 72) P-value
Demographic data
Age (years), median (IQR) 57 (42–70) 58 (43–70) 53 (32–65) 0.03
£ 15 years old, n/N (%) 27/360 (8) 18/288 (6) 9/72 (13) 0.09
Male, n/N (%) 143/360 (40) 108/288 (38) 35/72 (49) 0.09
Symptoms
Days ill, median (IQR) 3 (2–7) 3 (2–7) 3.5 (2–7) 0.70
Fever, n/N (%) 345/356 (97) 277/286 (97) 68/70 (97) 1.00
Rigors, n/N (%) 230/354 (65) 190/285 (67) 40/69 (58) 0.17
Headache, n/N (%) 197/355 (55) 161/286 (56) 36/69 (52) 0.50
Arthralgia, n/N (%) 118/355 (33) 95/286 (33) 23/69 (33) 0.90
Back pain, n/N (%) 123/355 (35) 99/286 (35) 24/69 (35) 0.90
Myalgia, n/N (%) 184/355 (52) 149/286 (52) 35/69 (51) 0.80
Retro-orbital pain, n/N (%) 16/340 (5) 15/275 (6) 1/65 (2) 0.32
Jaundice, n/N (%) 64/351 (18) 51/284 (18) 13/67 (19) 0.70
Nausea, n/N (%) 121/352 (34) 101/284 (36) 20/68 (29) 0.30
Vomiting, n/N (%) 99/352 (28) 82/284 (28) 17/68 (25) 0.50
Dysuria, n/N (%) 62/352 (17) 49/284 (17) 13/68 (19) 0.71
Diarrhea, n/N (%) 67/351 (19) 59/283 (21) 8/68 (12) 0.08
Constipation, n/N (%) 25/349 (7) 21/282 (7) 4/67 (6) 0.79
Abdominal pain, n/N (%) 100/346 (29) 84/280 (30) 16/66 (24) 0.30
Sore throat, n/N (%) 14/346 (4) 11/280 (4) 3/66 (5) 0.78
Drowsiness, n/N (%) 56/346 (16) 43/280 (15) 13/66 (20) 0.38
Risk factors, n/N (%)
Diabetes, n/N (%) 88/335 (26) 76/272 (28) 12/63 (19) 0.31
Excessive alcohol use, n/N (%) 34/317 (11) 27/257 (11) 7/60 (12) 0.79
Smoking, n/N (%) 37/311 (12) 28/253 (11) 9/58 (16) 0.34
Chronic renal failure, n/N (%) 18/341 (5) 11/278 (4) 7/64 (11) 0.05
Renal calculi, n/N (%) 20/336 (6) 12/275 (4) 8/61 (13) 0.01
TB, n/N (%) 6/236 (3) 5/195 (3) 1/42 (2) 0.92
HIV, n/N (%) 5/294 (2) 5/243 (2) 0/52 (0) 0.72
Steroid use, n/N (%) 14/303 (5) 11/252 (4) 3/52 (6) 0.80
Reported antibiotic use in the previous
week, n/N (%)
61/235 (26) 38/192 (20) 23/44 (52) < 0.001
Outcome
Discharged alive, n/N (%) 144/203 (71) 122/164 (74) 22/39 (56) 0.04
Died in hospital, n/N (%) 25/203 (12) 16/164 (10) 9/39 (23)
Discharged moribund, n/N (%) 34/203 (17) 26/164 (16) 8/39 (20)
ESBL = extended-spectrum beta-lactamase.
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should be changed. However, carbapenems are expensive and
not readily available in Laos and amikacin, although often used
when indicated, is potentially toxic, especially as therapeutic
drugmonitoring is not locally available. There is also a risk of the
emergence of resistance if these agents were more widely
used.45–47 Carbapenemase screening is already in place in
MahosotHospital.Wearecurrently investigating theuseof rapid
methods to detect ESBL production in patients with positive
blood cultures growing Gram-negative bacilli in the hope that
more targeted use of these valuable agents may be possible.
TABLE 3
Antimicrobial susceptibility of extended-spectrum beta-lactamase–producing Escherichia coli and Klebsiella pneumoniae isolated from blood
cultures between 2010 and 2014 at Mahosot Hospital, Vientiane, Lao PDR
Year 2010 2011 2012 2013 2014
P-valueAntimicrobial n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
Ampicillin 0/7 (0) 0/14 (0) 0/17 (0) 0/15 (0) 0/19 (0) NA
Co-amoxiclav 2/7 (29) 3/14 (21) 8/17 (47) 7/15 (47) 4/19 (21) 0.55
Cefalotin 0/7 (0) 0/14 (0) 0/17 (0) 0/15 (0) 0/19 (0) NA
Ceftazidime 1/5 (20) 3/12 (25) 4/14 (28) 2/15 (13) 4/19 (21) 0.96
Ceftriaxone 0/7 (0) 0/14 (0) 0/17 (0) 0/15 (0) 0/19 (0) NA
Ciprofloxacin 1/1 (100) ND ND 6/13 (46) 5/15 (33) 0.81
Chloramphenicol 4/7 (57) 7/14 (50) 8/17 (47) 9/15 (60) 13/19 (68) 0.51
Doxycycline ND ND ND 1/4 (25) 1/3 (33) 1.00
Gentamicin 5/7 (71) 3/14 (21) 8/17 (47) 8/15 (53) 10/19 (52) 0.15
Meropenem 6/6 (100) 12/12 (100) 15/15 (100) 15/15 (100) 17/17 (100) NA
Imipenem 7/7 (100) 13/13 (100) 13/13 (100) 15/15 (100) 15/15 (100) NA
Ofloxacin 4/7 (57) 5/14 (36) 9/17 (53) 8/15 (53) 6/19 (31) 0.53
Co-trimoxazole 0/7 (0) 3/14 (21) 4/17 (23) 4/15 (27) 3/19 (16) 0.70
Tetracycline ND 1/1 (100) ND 3/11 (27) 2/11 (18) 0.37
Amikacin 6/6 (100) 12/12 (100) 15/15 (100) 15/15 (100) 16/17 (94) 1.00
n = number of isolates susceptible to tested antimicrobial; N = total number of isolates tested; ND = not done; NA = not applicable. Figures in parentheses are percentages. Variations in
denominators reflect the fact that not all isolates were tested against each agent.
TABLE 2
Comparisonof characteristics andsymptomsofpatientswithESBL-positiveEscherichiacoliandKlebsiellapneumoniaebacteremia (data shownas
number (%) unless indicated)
Total (n = 72) ESBL—E. coli (n = 55) ESBL—K. pneumoniae (n = 17) P-value
Demographic data
Age (years), median (IQR) 53 (32–65) 56 (45–65) 24 (0.41–54) 0.0097
£ 15 year old, n/N (%) 9/72 (12) 2/55 (3.6) 7/17 (41) < 0.001
Male, n/N (%) 35/72 (49) 26/55 (47) 9/17 (53) 0.68
Symptoms
Days ill, median (IQR) 3.5 (2–7) 3 (2–7) 4 (2–7) 0.77
Fever, n/N (%) 68/70 (97) 55/55 (100) 13/15 (86) 0.04
Rigors, n/N (%) 40/69 (58) 34/54 (63) 6/15 (40) 0.11
Headache, n/N (%) 36/69 (52) 31/54 (57) 5/15 (33) 0.09
Arthralgia, n/N (%) 23/69 (33) 19/54 (35) 4/15 (27) 0.75
Back pain, n/N (%) 24/69 (35) 18/54 (33) 6/15 (40) 0.63
Myalgia, n/N (%) 35/69 (51) 30/54 (55) 5/15 (33) 0.12
Retro-orbital pain, n/N (%) 1/65 (2) 1/50 (2) 0/15 (0) 1.00
Jaundice, n/N (%) 13/67 (19) 12/52 (23) 1/15 (7) 0.26
Nausea, n/N (%) 20/68 (29) 17/53 (32) 3/15 (20) 0.52
Vomiting, n/N (%) 17/68 (25) 14/53 (26) 3/15 (20) 0.74
Dysuria, n/N (%) 13/68 (19) 11/53 (21) 2/15 (13) 0.71
Diarrhea, n/N (%) 8/68 (12) 6/53 (11) 2/15 (13) 1.00
Constipation, n/N (%) 4/67 (6) 4/53 (7) 0/14 (0) 0.57
Abdominal pain, n/N (%) 16/66 (24) 12/51 (23) 4/15 (27) 1.00
Sore throat, n/N (%) 3/66 (5) 2/51 (4) 1/15 (7) 0.54
Drowsiness, n/N (%) 13/66 (20) 10/51 (19) 3/15 (20) 1.00
Risk factor
Diabetes, n/N (%) 12/63 (19) 9/51 (17) 3/12 (25) 0.25
Excess alcohol, n/N (%) 7/60 (12) 6/48 (12) 1/12 (8) 1.00
Smokes, n/N (%) 9/58 (15) 8/46 (17) 1/12 (8) 0.66
Chronic renal failure, n/N (%) 7/64 (11) 6/50 (12) 1/14 (7) 0.91
Renal calculi, n/N (%) 8/61 (13) 7/47 (15) 1/14 (7) 0.63
Steroid use, n/N (%) 3/52 (6) 2/41 (5) 1/11 (9) 0.75
Reported antibiotic use in the previous
week, n/N (%)
23/44 (52) 18/35 (51) 5/9 (56) 1.00
Outcome
Discharged alive, n/N (%) 22/39 (56) 16/28 (57) 6/11 (55) 0.79
Died in hospital, n/N (%) 9/39 (23) 7/28 (25) 2/11 (18)
Discharged moribund, n/N (%) 8/39 (20) 5/28 (18) 3/11 (27)
ESBL = extended-spectrum beta-lactamase.
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Our study has several limitations. Because of its retro-
spective nature, some hospital charts could not be retrieved,
and so it was not possible always to capture data about risk
factors, comorbidities, and clinical outcomes related to ESBL-
E bacteremia. Second, this study was carried out in a single
center and might not be applicable to other settings across
Laos. Third, the estimated number of presumed hospital-
acquired bacteremias is small and possibly exaggerated
(maximum10%overall) andwehave, therefore, not attempted
to analyze the data by whether episodes were hospital or
community acquired. Furthermore, blood cultures are not al-
ways collected on admission. Reported antibiotic use data are
also limited in scope, particularly timings and class. Last, the
data relate to 2010–2014 and because the epidemiology of
AMR is likely to be changing constantly, expanded surveil-
lance is essential.
CONCLUSION
Our study has demonstrated an alarming increase in the
incidence of ESBL-producing E. coli and, to a lesser extent
K. pneumoniae, bacteremia in Laos. Because most isolates
were multiresistant, the effectiveness of antibiotics that are
commonly used in the local setting is compromised. This
emphasizes the need for appropriate local antibiotic guide-
lines based on accurate knowledge of local resistance pat-
terns to improve patient outcomes and the importance of
efforts to promote antimicrobial stewardship in Laos before
the levels of AMR reach those of neighboring countries.
In addition, more detailed and ongoing AMR surveillance
and research in the Lao PDR are also required, to build on this
limited study.
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